Close
Digital Health & Ai Innovation summit 2026
Medical Taiwan 2026

Huma and AstraZeneca Partner to Accelerate Innovation for Digital-First Patient Care

MSU Health Care Taps Epion Health to Drive Digital Patient Access

Huma Therapeutics Limited, a global digital health technology company advancing digital-first care delivery and research to help people live longer, fuller lives, announced a new partnership with AstraZeneca to scale innovation for digital health. This agreement follows prior use cases executed between Huma and AstraZeneca, reflecting a shared ambition to improve clinical outcomes through digital health solutions to bridge the gap between patients and clinicians.

As part of this partnership, Huma and AstraZeneca will launch Software as a Medical Device (SaMD) companion apps targeted at several therapeutic areas and will partner to help accelerate adoption of decentralized clinical trials. These will build on Huma’s proven technologies which already power digital-first care serving more than 1.8 million active patient users across more than 3,000 hospitals and clinics. Huma’s technologies are designed to connect with clinical workflows, allowing for more efficient care delivery.

“Our track record of scaling innovation has set the stage for this important partnership with one of the world’s largest biopharmaceutical companies. I am excited to have AstraZeneca’s support to build upon our 10-year experience of delivering digital-first solutions across healthcare and clinical trials,” said Dan Vahdat, CEO of Huma. “The combination of pioneering leadership, global-reach, deep medical knowledge and digital innovation will enable our award-winning1 platform to help more people live longer, fuller lives.”

This collaboration marks an important moment as it is a first for AstraZeneca in the digital health space as well as in the industry for chronic diseases and SaMDs in support of different treatments,” said Karan Arora, Chief Commercial Digital Officer, AstraZeneca. “With Huma, we are accelerating AstraZeneca’s ambition to achieve earlier diagnosis and treatment for patients with chronic diseases so they can lead better, more fulfilling lives.”

Ninety-five percent of care for chronic conditions happens outside the clinical setting2, highlighting the need for more digital-first care. AstraZeneca has invested in the development and clinical validation of the patient centered AMAZE chronic disease management platform to improve the care of patients. AstraZeneca has used the AMAZE platform to conduct clinical studies at leading U.S. academic medical centers with the goals of improving patient engagement, care-team communication and clinical outcomes while reducing healthcare costs. The collaboration with Huma will leverage the strong foundations and early success of AMAZETM to accelerate digital-first care across therapeutic areas and launch SaMDs.

“We are very excited to be working more closely with Huma across our digital health initiatives,” said Ruud Dobber, Executive Vice President and President, Biopharmaceuticals Business Unit, AstraZeneca. “We believe digital can expand access to healthcare, advance clinical research, and identify existing gaps in care. Additionally, with this innovative partnership, we will bring a combination of technology along with expertise in research and drug development to global decentralized clinical trials advancing the science of right patient, right therapy, right time.

About Huma

Huma Therapeutics is a global digital health technology company that advances digital-first care delivery and research to help people live longer, fuller lives. Huma’s award-winning modular platforms are used by more than 3,000 hospitals and clinics, with 1.8 million active users. Huma’s offering works across different disease areas and powers:

 

Experts Feel COVID-19 Vaccine May Well Become A Yearly Jab

ICPA Health Products Ltd Pledges Support Towards India's Largest Vaccination Drive

Public health experts aren’t sure what the future has in store for COVID-19 immunizations, but some think it’s becoming increasingly likely that these doses will be required on an annual basis, similar to the way flu shots are advised each fall. As more data gets rolled-in, the clearer it will become, says Chicago Medical School’s Dean, Dr. Archana Chatterjee. She goes on to say that, however, the jab will be needed on a regular basis to keep the virus under check. We’ll probably need some kind of vaccination on a regular basis to keep it under control, opines Dr. Chatterjee. She adds that one doesn’t know whether this will be done annually, every two years, or every five years.

The committee will meet on April 6 to consider the future necessity of COVID-19 vaccine booster doses, as well as how often, if at all, they would be required. According to the FDA, it is expected that representatives from the US Centers for Disease Control and Prevention and the National Institutes of Health will also attend the meeting. The meeting is designed to aid the FDA in establishing a “basic outline” that will indicate whether more COVID-19 vaccine booster doses could be required and what might justify altering the mix of vaccinations to specifically target coronavirus strains. There would be no formal vote, and there would be no discussion of product authorization or approval.

Biologics Evaluation and Research of FDA Director, Dr. Peter Marks, says that by bringing together the panel of professional scientific external advisers in an open, public discussion about booster vaccination, they will obtain valuable knowledge, input, and expert counsel as one begins to correlate apt regulatory strategies to solve COVID-19 and virus variations in the future.

Former FDA Commissioner Dr. Scott Gottlieb said that he believes this is a six-month vaccine in terms of delivering really important protection against symptomatic sickness and infection, and for the vast majority of Americans, it is expected to become an annual phenomenon.

Dr. Abraar Khan, from Stanford University, says that it may be predicted that the virus will not go away, that there will be repeated surges, and that the protection will fade with time. As a result of the declining protection and the virus’s evolution, future outbreaks are unpredictable, as per him, and thus there will be a need for boosters once more in the future, probably later this year, and they will have to be tailored to the most current strain that’s circulating.

Pfizer and Moderna, for example, are working on variant-specific vaccinations that might target whatever variation of the SARS-CoV-2 virus is prevalent at the time the booster is needed.The companies have stated that they are developing a vaccine to guard against the Omicron form, but it is unclear whether one is required.

Pfizer CEO Albert Bourla stated that the company hopes to develop a vaccine that protects against Omicron and other SARS-CoV-2 strains. Bourla had said earlier this month that the goal is to produce something that can defend for minimum a year at least, and once that is done, one can return to the way life was led.

Type 2 Diabetes A Real Possibility Due To Severe COVID-19

DreaMed's AI solution for diabetes expands across the US

According to a major assessment of patient records released recently, people who had COVID-19 were more likely to develop Type 2 diabetes in a year than those who dodged the coronavirus. As per scientists who evaluated the data of over 181,000 Department of Veterans Affairs patients diagnosed with COVID-19 between March 1, 2020, and Sept. 30, 2021, the discovery is true, including for people who had less severe or asymptomatic forms of coronavirus infection, though the chances of developing new-onset diabetes increased as the severity of COVID symptoms increased.

Their findings were compared to the medical records of almost 4.1 million VA individuals who were not affected at the time and another 4.28 million who got VA medical treatment in 2018 and 2019. This study was unable to prove causes, but it did reveal a substantial link between the two disorders. Overall, patients diagnosed with COVID-19, a coronavirus-related condition, were 46% more likely to develop Type 2 diabetes for the first time or be prescribed blood glucose treatment, according to the study. The research was published in the medical journal Lancet Diabetes & Endocrinology.

In other words, 2 out of every 100 COVID patients were much more prone to diabetes, a condition in which the pancreas produces inadequate amounts of the hormone insulin, resulting in poorly managed blood sugar levels. This diabetes type can harm the kidneys, nerves, blood vessels, and heart, among other things. The findings have ramifications for more than 471 million people who were infected during the epidemic, nearly 80 million of whom were in the United States, and notably for long-haul COVID sufferers.

General people should pay attention to their blood sugar if they’ve had COVID-19, opines VA St. Louis Health Care System’s chief of R & D, Ziyad Al-Aly, who conducted the study. Earlier, smaller studies and clinicians who have managed COVID patients have reported a rise in new diabetes diagnoses related to coronavirus infection. Al-Aly, on the other hand, Al-Aly stated that his study was the largest on the subject, and that it looked at the longest period of time from 31 days post infection to an average of nearly 1 year per patient.

VA patients are older than the average population, and they are more male and older than the general population. Nonetheless, Al-Aly said the vast number of people participating gave him trust that his findings could be applied to the general public. The risk seemed clear in all groupings, noted Al-Aly, including women, non-whites, younger people, and those of different BMIs.

More than 99 percent of affected VA patients developed Type 2 diabetes, as compared to Type 1, which occurs when the pancreatic’ insulin-producing cells stop generating the hormone entirely. Al-Aly theorised that the cells’ reduced effectiveness was caused by inflammation, which could have been induced by the virus or the body’s response to it. Together, present evidence demonstrates that diabetes is an aspect of the complicated extended COVID syndrome, as per the researchers, and that post-acute care efforts for people with COVID-19 should include diabetes identification and management.

MedWise Urgent Care Partners with athenahealth to Support its Growing Network of Clinics

MedWise Urgent Care Partners with athenahealth to Support its Growing Network of Clinics

athenahealth, Inc., a leading provider of network-enabled software and services for medical groups and health systems nationwide, and MedWise Urgent Care announced an expanded partnership through which MedWise will utilize athenaOne’s Medical Coding solution to help reduce administrative burden, maintain and enhance the patient experience, and improve financial performance throughout its growing network of specialized urgent care clinics.

Through the expanded partnership, athenaOne’s Medical Coding solution will support MedWise as it executes its ambitious growth plan. athenaOne’s Medical Coding solution is designed for practices and medical groups looking to reduce the administrative burden of medical coding that slows them down and delays claim submissions, freeing them to spend more time with patients.

Since MedWise opened the doors to its first clinic in 2020, it has used athenaOne, athenahealth’s cloud-based suite of healthcare products, to support its innovative approach to delivering care. In just two years, MedWise has grown to nine clinics across Tulsa, Oklahoma, with several more expected to open soon. Through its clinics, MedWise’s mission is to provide convenient, accessible care with a retail-focused, patient-friendly experience.

“We are proud to partner with MedWise as it continues to grow and deliver its unique care model,” said Bob Segert, chairman and chief executive officer of athenahealth. “By removing much of the administrative burden from MedWise’s clinics, athenaOne equips providers and staff with the resources they need to focus on delivering superior, convenient care to their patients.”

“athenahealth has been an amazing partner from day one, supporting us through our launch and growth, despite significant challenges during the pandemic,” said Patrick Aguilar, chief medical officer of MedWise. “When our growth moved faster than our internal billing and coding capabilities, athenahealth stepped up to ensure we could continue to expand while also allowing our providers to focus more of their time and energy on our patients.”

About athenahealth, Inc.

athenahealth creates innovative healthcare technology that connects clinicians, patients, payers, and partners in differentiated ways. Our electronic health records, revenue cycle management, and patient engagement tools allow anytime, anywhere access, driving better financial outcomes for our customers and enabling our provider customers to deliver better quality care. In everything we do, we’re inspired by our vision to create a thriving ecosystem that delivers accessible, high-quality, and sustainable healthcare for all.

Steward alf Global Healthcare wins contract for new hospital in Saudi Arabia

Summit BHC acquires West Virginias Highland Hospital

Steward alf Global Healthcare Company has secured an operations contract from the Red Sea Development Company (TRSDC) for a new Coastal Village Hospital in Saudi Arabia.

The company is a joint venture between Alfanar’s health care arm Alf Healthcare and Steward Health Care International.

Located in the Coastal Village area of The Red Sea Project, the hospital will provide primary and secondary healthcare services to Coastal Village’s residents.

It will offer healthcare services to about 14,000 people in the community working in and around the 1.5 million metre square waterfront site.

TRSDC stated that the Coastal Village Hospital will also offer emergency care, clinical support, family medicine, women’s health, radiology, and pharmacy services.

Steward alf Global Healthcare Company will be responsible for the development of site-wide emergency response provision as part of the contract.

It will also provide support in the design, building, and commissioning of the hospital.

As an integrated part of the Emergency Department of the facility, a hyperbaric chamber will also be operated, to provide primary treatment for diving accidents, like decompression sickness.

TRSDC CEO John Pagano said: “The Coastal Village is envisioned as a sustainable community of homes and amenities, complete with newly opened offices and a management hotel.

“It forms a central hub in which our employees can live, work and relax, and with the Coastal Village Hospital at its center, we can ensure an exceptional quality of life for our residents.

“Our people are our priority, and we care about the health and well-being of each and every employee. Steward alf Global Healthcare Company combines the local experience of Alfanar with international best practice from Steward Health Care International, guaranteeing the very best of medical care is provided.”

 

PE GI Solutions Enters into a Strategic Partnership with Emerson Hospital to Open Emerson Endoscopy & Digestive Health Center

PE GI Solutions Enters into a Strategic Partnership with Emerson Hospital to Open Emerson Endoscopy & Digestive Health Center

PE GI Solutions entered into a strategic partnership with Emerson Hospital to open Emerson Endoscopy & Digestive Health Center. The brand-new center is officially recognized as an accredited center by The Joint Commission and is now accepting patients.

Emerson Endoscopy & Digestive Health Center earned The Joint Commission’s Gold Seal of Approval® for Ambulatory Surgery Center Accreditation by demonstrating compliance with its performance standards. The Gold Seal of Approval® is a symbol of quality that reflects a health care organization’s commitment to providing safe and quality patient care.

Emerson Endoscopy & Digestive Health Center is a spacious, state-of-the art facility that provides patient-centered care and necessary procedures in a comfortable setting. The facility is equipped with cutting-edge equipment and is the only hospital-owned outpatient endoscopy center in the region. The Center complements Emerson’s hospital-based endoscopy unit, allowing patients the choice of being treated in the hospital or outpatient setting.

Three experienced, fellowship-trained gastroenterologists will be performing procedures at the Emerson Endoscopy & Digestive Health Center: John Dowd, DO; Andrea Fribush, MD; and Jennifer Nayor, MD.

“We focused on leveraging the strategic partnership to create a safe and efficient experience for all patients, which is our top priority. Partnering with PE GI Solutions has allowed us to tap into their extensive expertise in the GI ambulatory surgery center (ASC) community,” said Dr. John Dowd, Medical Director of Endoscopy at Emerson Hospital and Co-Medical Director of Emerson Endoscopy & Digestive Health Center.

Emerson Hospital entered into the strategic partnership with PE GI Solutions to leverage and utilize their management services. The PE Center Solutions platform offers a number of opportunities for GI physicians, health systems, and hospitals to build, develop, and optimize a new or existing GI-specific ASC.

“A strategic partnership with Emerson Hospital was carefully executed to ensure the overall goal of providing the highest level of patient care at an ASC. We are excited to team with Emerson, a leading independent community hospital just outside of Boston, Massachusetts, that has a deep clinical affiliation with Mass General Brigham,” said Rob Puglisi, VP of Operations at PE GI Solutions. “We look forward to continuing our work together as patients come to Emerson Endoscopy & Digestive Health Center for their GI procedures.”

Emerson Endoscopy & Digestive Health Center is located at 310 Baker Avenue, Concord, Massachusetts, a short drive from Emerson Hospital. The hours of operations are Monday-Friday, 7:00am-5:00pm. To contact the office, please call (978) 776-1710.

For more information about the partnership of PE GI Solutions and Emerson Hospital, please visit the company’s website here. For more information about Emerson Endoscopy & Digestive Health Center, please visit emersongi.org.

About PE GI Solutions (Formerly known as Physicians Endoscopy)

PE GI Solutions specializes in providing integrated business strategies and insights for GI specialists and healthcare partners to help their practices, ASCs and ancillary services grow and thrive through professional management, aligned investments, and strategic partnerships. PE GI Solutions’ physician partners leverage the PE Practice Solutions and PE Center Solutions platforms to gain access to centralized resources and operational efficiencies that drive growth and positively impact physician and patient experiences—all while preserving the independent practice of medicine. Recognized as the largest single-specialty developer, investor, and manager, PE GI Solutions is the trusted business partner and advisor exclusively serving gastroenterologists for over 20+ years.

About Emerson Hospital

Emerson Hospital is a multi-site health system headquartered in Concord, Mass., with a 179-bed hospital, outpatient medical centers in Sudbury, Groton and Westford, and urgent care centers in Hudson and Littleton. Emerson provides advanced health care to more than 300,000 individuals in 25 towns.

Artio Medical Receives FDA Clearance for Solus Gold Embolization Device

Artio Medical Receives FDA Clearance for Solus Gold Embolization Device

Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, today announced it received US FDA clearance for its Solus Gold Embolization Device, a next-generation product for peripheral vascular occlusion.

“Current occlusion devices can be difficult to position in challenging anatomy, often require multiple implants, and usually take time to completely occlude the target vessel. This can be a problem when physicians need to control or prevent bleeding and reduce the risk of further complications,” commented Dr. Blaise Baxter, Vice President of Neurovascular and Peripheral Vascular Interventions for Artio Medical. “The Solus Gold device aims to overcome these limitations with a single implant designed for precision placement and immediate occlusion, even in high-flow vessels and short landing zones.”

The Solus Gold Embolization Device is indicated to obstruct or reduce the rate of blood flow in the peripheral vasculature. The delivery system balances flexibility and pushability, enabling physicians to navigate tortuous vasculature. Following a controlled expansion and simple mechanical detachment, the non-porous, balloon-like gold implant provides 360° vessel apposition for immediate and complete occlusion, and resists migration and recanalization, providing physicians with a “one-and-done” solution for peripheral vascular occlusion.1,2 As demonstrated in a GLP pre-clinical study, the Solus Gold device achieved immediate occlusion in > 90% of cases, including in large and high flow vessels, and demonstrated 0% migration and 0% recanalization in testing out to 3 months.1

“We would like to thank the FDA for providing helpful input to the Artio team through the Q-Submission process, and for the careful and thoughtful review of our 510(k) application. I would also like to thank the talented and dedicated Solus Gold product development team at Artio, our many partners in the industry, and our supportive investors for helping Artio reach this important milestone,” said F. Nicholas Franano, MD, President and CEO of Artio Medical. “When I first learned to embolize vessels using small metal coils more than 20 years ago, I thought surely someone will come up with a better device for doing that. As we prepare for the market release of the Solus Gold device later this year, I am excited to have the opportunity to provide physicians and patients with an improved peripheral vascular embolization experience.”

About Artio Medical
Artio Medical is a medical device company committed to developing innovative products for the treatment of peripheral vascular, neurovascular, and cardiology diseases.

About the Solus Gold Embolization Device
Continued blood flow through damaged or diseased blood vessels can result in life-threatening bleeding and other serious medical conditions. Peripheral vascular embolization is a minimally invasive procedure that blocks or reduces blood flow in blood vessels. The Solus Gold Embolization Device combines a flexible catheter assembly and a non-porous, balloon-like gold implant for easy delivery, precise placement, and immediate vessel occlusion.

Pixee Medical Announces the Commercial Launch of Knee+ in the USA

Pixee Medical Announces the Commercial Launch of Knee+ in the USA

Pixee Medical, a pioneer in augmented surgical guidance technology, has announced that its Knee+ AR computer-assisted orthopedic solution is going to be commercially available in the USA with a perfect fit for Ambulatory Surgical Centers (ASCs) need.

Knee+ is a patented platform designed to help orthopedic surgeons perform surgery through the real-time 3D positioning of instruments, right in their field of view. Knee+ is intuitive and consists of proprietary software using a unique proprietary tracking system running on off-the-shelf smart glasses, with no bulky capital equipment or disposables required.

This solution was launched commercially in January 2021 in Europe and Australia. In the challenging COVID context, without any commercial promotion, the product was quickly adopted, with more than 100 systems sold thanks to an easy-to-use and scalable solution.

“Since our first surgery in the USA in Boston in October 2021, we have organized a successful round of surgeries on multiple clinical sites across the USA. We are now ready and confident to launch the product in the leading worldwide market for orthopedics” states Sébastien Henry, Founder and CEO of Pixee Medical. “Our solution is the only imageless & open platform for total knee surgery available in the US.”

“We will be at the AAOS Meeting to meet with surgeons and finalize the organization of our distribution channel.”

Pixee will soon be adding new features to its Knee+ platform, with soft tissue balancing, kinematic alignment and data connectivity. It will also be expanding its portfolio with a mixed reality product for total shoulder arthroplasty and with an easy-to-use cup orientation and leg length controlling AR tool for total hip arthroplasty. Knee+ is now compatible with surgical hoods.

Eko Launches Screening Solution to Help Catch Heart Disease Early

Eko Launches Screening Solution to Help Catch Heart Disease Early

Eko, a digital health company advancing heart and lung disease detection, announced the launch of its newly-redesigned Eko App, which will transform patient interactions into an opportunity to screen for cardiovascular disease. Heart disease is the leading cause of death in the U.S., and there has not been an efficient and affordable solution to screen for heart disease at the physical exam until now.

“Current clinical workflows for detecting heart disease often include expensive tests performed by a specialist in an emergency setting, which makes early diagnosis nearly impossible,” said Dr. Adam Saltman, Chief Medical Officer, Eko. The physical exam offers an opportunity for early detection of heart disease. However, as many as 80% of abnormal heart sounds go unrecognized when exams are performed with a traditional stethoscope. This can delay life-saving treatments for patients.”

Eko has transformed the traditional stethoscope into an intelligent disease detection tool to help clinicians spot cardiovascular disease easier during the physical exam. Their line of smart stethoscopes, when paired with its accompanying automated disease detection software using the Eko App, analyzes heart sounds with FDA-cleared and clinically proven AI algorithms.* In seconds, the algorithms can detect heart murmurs and atrial fibrillation (AFib)** with comparable performance to human experts.

“Frontline healthcare professionals are our best line of defense in catching cardiovascular disease early on, but they are challenged to do so by outdated tools, insufficient time, and inadequate resources,” said Connor Landgraf, CEO and Co-founder, Eko. “With a disease that is so pervasive in our society, it is imperative that we provide every healthcare professional with a solution that helps them diagnose with more confidence and give their patients the best care possible. This is how we’ll save millions of lives in the coming years.”

Eko’s AI algorithm to identify heart murmurs, a leading indicator of heart valve disease, was clinically validated to perform at a sensitivity of 87.6% and specificity of 87.8%. Their algorithm for detecting atrial fibrillation performed at a sensitivity of 98.9% and a specificity of 96.9%. Real-world validation of Eko’s heart murmur detection algorithm came from a recent, peer-reviewed publication in the Journal of the American Heart Association. It was the largest study on AI analysis of cardiac murmurs to date.

“Eko’s technology has given me the added assurance to detect and verify heart murmurs and atrial fibrillation in my patients,” said Joanna Kmiecik, MD, Family Medicine Specialist. “The ease-of-use and portable nature of Eko’s products helps me to examine patients right in my office, with minimal impact to my physical examination routine. If I hear a heart sound suspicious of disease, Eko accurately confirms it in seconds. This helps me to determine care decisions and refer to a specialist confidently when appropriate. My patients even enjoy how they can engage with the app, and I feel I am a better clinician.”

Synergy Biomedical Launches BIOSPHERE Flex SP Extremities, Synthetic Bioactive Bone Graft

Synergy Biomedical Launches BIOSPHERE Flex SP Extremities, Synthetic Bioactive Bone Graft

Synergy Biomedical, LLC, a developer of innovative biomaterial products, announced the launching of BIOSPHERE® FLEX SP EXTREMITIES, Synthetic Bioactive Bone Graft. Using Synergy’s proprietary BIOSPHERE® Technology, BIOSPHERE® FLEX SP Extremities is a sheet putty composed of innovative spherical bioactive glass granules combined with a porous collagen/sodium hyaluronate carrier. This product addition adds to the already highly successful Synergy FLEX sheet putty product portfolio. Flex SP Extremities expects to be an integral solution into the Upper and Lower Extremity market.

BIOSPHERE® FLEX SP EXTREMITIES is a third-generation bioactive glass bone graft solution. Specifically developed to maximize the bone healing potential of bioactive glass. Utilizing the well-known and trusted 45S5 bioactive glass composition that has been proven to be an effective bone graft material. FLEX SP EXTREMITIES is a sheet putty that is easy to handle, flexible and moldable (once hydrated) to aid in surgical placement. Designed to accommodate bone marrow aspirate and is available in small and medium sizes.

“The Launch of BIOSPHERE® FLEX SP EXTREMITIES, Synthetic Bioactive Bone Graft is a major step forward for our company into the extremity market,” stated CEO Kevin Booth. “Synergy’s approach from the start has been to clearly understand the key basic science first for maximizing bone healing and then develop innovative biomaterial products. Choosing the correct bone graft can be one of the most crucial decisions for upper and lower extremity applications and FLEX SP EXTREMITIES will provide surgeons confidence in that decision due to the clinical success behind BIOSPHERE® Technology.”

BIOSPHERE® FLEX SP EXTREMITIES utilizes patented bioactive glass spheres that have been shown in vivo to result in faster and more robust bone formation. The product provides surgeons with a moldable bone graft material (once hydrated) that has one of the highest bioactive glass contents on the market.

1...337338339...1,128Page 338 of 1,128

About us

Hospital & healthcare Management is a leading B2B arena designed for the healthcare sector, it allow members to reach both ends of the healthcare facility procurement chain. . . Read More

Subscribe us

System

Resources

Archive Links

Subscribe

Copyright © 2008 - 2026 Hospital & Healthcare Management. All rights reserved. Publication of Leo Marcom Pvt Ltd.

Translate »